Rabies Vaccination Reaction
Conditions
Keywords
Rabies Vaccination, Arachidonic acid, efficacy
Brief summary
This study intends to use a randomized controlled trial design to vaccinate all participants against rabies and perform ARA interventions during vaccination to test the efficacy, safety, and intestinal flora of each group after immunization.
Detailed description
Rabies is an acute zoonotic infectious disease caused by central nervous system invasion by rabies virus. At present, there is still a lack of effective treatment, and once clinical symptoms appear, it is almost 100% fatal. Rabies vaccination within 24 hours of exposure may reduce the incidence of rabies. Pre-exposure prophylaxis is also effective, and the current recommended pre-exposure vaccination program in China is 0 days, 7th day, 21st days. The health of the human body is inseparable from various nutrients. There are studies suggesting that arachidonic acid(ARA) has an immunomodulatory effect, but there is limited evidence for its effect on vaccines. Therefore, this study will explore the effects of nutritional supplements on the effectiveness of rabies vaccination.
Interventions
DIETARY_SUPPLEMENTArachidonic acid
D3 ARA group will receive ARA capsules from the third day of the study. D6 ARA group will receive ARA capsules from the sixth day of the study
DIETARY_SUPPLEMENTSunflower oil
The placebo group and D6 ARA group will receive sunflower oil capsules from the third day of the study. D6 ARA group will stop receiving sunflower oil capsules from the fifth day of the study.
BIOLOGICALRabies Vaccine (Vero Cell) for Human Use
Every participant will receive three doses of rabies vaccination.
Sponsors
Tsinghua University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* 1）18-45 years old; * 2）BMI 18.5-24.9 kg/m2; * 3）Have not received rabies vaccination.
Exclusion criteria
* 1\) Those who have severe disorders of abnormal lipid metabolism; * 2\) Those who have used lipid-lowering drugs, weight loss drugs, and insulin drugs in the past three months; * 3\) Those who have received other vaccines in the past three months; * 4\) Those who have used probiotics or prebiotics in the past three months; * 5\) Those who have used steroids and immunosuppressants, other hormonal drugs in the past year; * 6\) Those with immunodeficiency diseases; * 7\) Those with a history of severe vaccine allergies; * 8\) Those who have disorders of liver and kidney metabolism; * 9\) Those who have had fever, cold, severe diarrhea and other diseases in the past month. * 10\) Smokers in the last year.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes of rabies virus antibody titers | Day 6, 13, 16, 19, 26 of the study | specific antibody titers |
| Changes of neutralizing antibody titers | Day 6, 13, 16, 19, 26 of the study | To test the ability of binding to rabies virus |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Routine analysis of intestinal flora: alpha diversity | Day 3 and day 19 of the study | The alpha diversity of microbiota in feces samples will be examined to explore the potential gut-immune response caused by intervention. |
| C-reactive protein | Day 6, 13, 16 and 19 of the study | to test the potential C-reactive protein changes triggered by ARA supplementation |
| Routine analysis of intestinal flora: beta diversity | Day 3 and day 19 of the study | The beta diversity of microbiota in feces samples will be examined to explore the potential gut-immune response caused by the intervention. |
| Routine analysis of intestinal flora: species abundance histogram | Day 3 and day 19 of the study | The species abundance histogram of microbiota in feces samples will be examined to explore the potential gut-immune response caused by the intervention. |
| Routine analysis of intestinal flora: Lefse | Day 3 and day 19 of the study | The Lefse of microbiota in feces samples will be conducted to explore the potential gut-immune response caused by the intervention. |
| Routine analysis of intestinal flora: PLS-DA | Day 3 and day 19 of the study | The PLS-DA of microbiota in feces samples will be conducted to explore the potential gut-immune response caused by the intervention. |
| Routine analysis of intestinal flora: KEGG pathway | Day 3 and day 19 of the study | The KEGG pathway microbiota in feces samples will be analyzed to explore the potential gut-immune response caused by the intervention. |
| Routine analysis of intestinal flora: differential KO expression | Day 3 and day 19 of the study | The differential KO expression microbiota in feces samples will be analyzed to explore the potential gut-immune response caused by the intervention. |
| Macrogenomic sequencing difference of intestinal flora | Day 3 and day 19 of the study | The macrogenomic sequencing analysis of microbiota in feces samples will be conducted to explore the potential gut-immune response caused by the intervention. |
| Fecal fatty acid content | Day 3 and day 19 of the study | The fatty acid content in feces samples will be examined to explore the change of fatty acid intake caused by the intervention. |
| serum blood fatty acid profiles | Day 6, 13, 16，19 of the study | to test the change of fatty acid profiles after intervention |
Other
| Measure | Time frame | Description |
|---|---|---|
| Blood count: white blood cells | tested on day 3 and day 19 of the trial. | To evaluate the intervention safety. |
| Blood count: hemoglobin | tested on day 3 and day 19 of the trial. | To evaluate the intervention safety. |
| Blood count: hematocrit | tested on day 3 and day 19 of the trial. | To evaluate the intervention safety. |
| Blood count: platelets | tested on day 3 and day 19 of the trial. | To evaluate the intervention safety. |
| Anxiety | tested on day 13 of the trial. | Evaluated with General Anxiety Disorder-7 items. The scores are between 0 to 21, higher scores mean a worse outcome. |
| Depression | tested on day 13 of the trial. | Evaluated with Patient Health Questionaire-9 items. The scores are between 0 to 27, higher scores mean a worse outcome. |
| Blood count: red blood cells | tested on day 3 and day 19 of the trial. | To evaluate the intervention safety. |
| Serum triglyceride levels | Days 3 and day 19 of the study. | To examine the changes of blood lipids in blood after intervention and evaluate the intervention safety. The spacific measurements include: Triglycerides (TG), high-density lipoprotein cholesterol (HDL-CHO), low-density lipoprotein cholesterol (LDL-C), and total cholesterol (TC). |
| Adverse events by ARA | Day 3 to day 30 of the trial. | To examine the safety of using ARA, including allergy, gastrointestinal discomfort and others. |
Countries
China
Outcome results
None listed